logo

Xencor Inc (XNCR)



Trade XNCR now with
  Date
  Headline
9/10/2019 4:05:44 PM Xencor Appoints Celia Eckert As VP, General Counsel And Corporate Secretary
8/7/2019 10:09:14 AM Wedbush Is Cutting Xencor Inc (XNCR) FY20 Rev. Estimate To 83.4 M From 90.6 M
8/7/2019 10:09:02 AM Wedbush Is Lowering Xencor Inc (XNCR) Q3 20 Rev. Estimate To 80.6 M From 82.3 M
8/7/2019 10:08:40 AM Wedbush Is Lowering Xencor Inc (XNCR) Q1 20 Rev. Estimate To 2.0 M From 3.9 M
8/7/2019 10:08:25 AM Wedbush Is Raising Xencor Inc (XNCR) FY19 Rev. Estimate To 135.5 M From 123.6 M
8/7/2019 10:08:11 AM Wedbush Is Lowering Xencor Inc (XNCR) Q4 19 Rev. Estimate To 2.0 M From 3.9 M
8/7/2019 10:08:03 AM Wedbush Is Cutting Xencor Inc (XNCR) Q3 19 Rev. Estimate To 2.0 M From 3.9 M
8/7/2019 10:07:25 AM Wedbush Is Cutting Xencor Inc (XNCR) FY20 Estimate To -1.17 From -0.77
8/7/2019 10:01:47 AM Wedbush Is Cutting Xencor Inc (XNCR) FY19 Estimate To -0.14 From -0.13
8/7/2019 9:59:36 AM Wedbush Is Lowering Xencor Inc (XNCR) Q4 19 Estimate To -0.65 From -0.54
8/7/2019 9:57:58 AM Wedbush Is Cutting Xencor Inc (XNCR) Q3 19 Estimate To -0.63 From -0.51
6/27/2019 8:07:15 AM Xencor: Paul Foster, SVP And Chief Medical Officer, Plans To Retire
5/23/2019 8:13:59 AM Xencor Appoints Jeremy Grunstein VP, Business Development
5/6/2019 8:13:13 AM Xencor Doses First Patient In Phase 1 Study Of XmAb®23104 For Patients With Advanced Solid Tumors
4/2/2019 8:08:15 AM Xencor Enters Research And License Agreement With Astellas Pharma
3/8/2019 8:06:18 AM Xencor Closes Research Collaboration And License Agreement With Genentech
2/26/2019 8:40:02 AM Wedbush Is Raising Xencor Inc (XNCR) Q4 19 Estimate To -0.40 From -0.41
2/26/2019 8:39:49 AM Wedbush Is Cutting Xencor Inc (XNCR) Q1 19 Estimate To 1.37 From 1.38
2/25/2019 4:33:10 PM Xencor Q4 Net Loss $18.2 Mln Or $0.32/Shr Vs Net Income $7.4 Mln Or $0.15/Shr Last Year
  
 
>